Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug ...Middle East

Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer. The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV. Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing. Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million. Glenmark's current portfolio consists o

Read More Details
Finally We wish PressBee provided you with enough information of ( Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug )

Also on site :

• Trump administration moves to upend $37B affirmative action program
• Elon Musk says Trump's spending bill undermines the work DOGE has been doing
• China's Steel Export Surge Appears to Have Peaked